Injectable HIV treatment as a switch from daily pills
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are living with HIV and currently take daily HIV medication (antiretroviral therapy).
- Your HIV viral load has been undetectable (too low to measure) for at least the past 6 months.
- You are willing to switch from daily pills to a long-acting injectable (shots) every month or every two months.
- You must not have had a previous treatment failure or known drug resistance to this class of medications.
- You are not pregnant or planning to become pregnant, and you do not have a known hepatitis B infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people living with HIV feel about switching to a new injectable treatment called cabotegravir and rilpivirine. It aims to understand real-life experiences and quality of life after making the switch.
This study looks at how the long-acting injectable treatment for HIV affects your quality of life and how well it keeps the virus under control. If you've already completed the injections, you'll be asked to complete questionnaires about your experiences.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Hear when a new Patient Satisfaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.